AOD-9604 Metabolic

Metabolic Pharmaceuticals developed AOD-9604 for obesity treatment, with Phase IIa trials underway as of 2002 for this lipolytic peptide fragment of human GH.

Abstract

Metabolic is developing AOD-9604 for the potential treatment of obesity.. By February 2002, phase IIa trials were underway.

Key Findings

Metabolic is developing AOD-9604 for the potential treatment of obesity. | By February 2002, phase IIa trials were underway.

Study Design

Phase 2 clinical trial